Czownicki Z, Pasz P, Michałek A, Zientek J, Zientek A, Koźlik H
Poradni Onkologicznej Zespołu Zakładów Opieki Zdrowotnej w Cieszynie.
Pneumonol Alergol Pol. 2000;68(9-10):411-6.
Recent studies have pointed out that chemotherapy can prolong life in advanced inoperable cancer patients. A clinical study to evaluate response and toxicity of the combination of etoposide, ifosfamide and cisplatin (EIP) in the treatment of inoperable non-small cell lung cancer was performed. 25 patients entered the study. Treatment consisted of etoposide 120 mg/m2 given i.v. on days 1-3, ifosfamide 1.5 g/m2 given i.v. on days 1-5 with mesna protection and cisplatin 20 mg/m2 given i.v. on days 1-5. Cycles were repeated every 4 weeks for a maximum of 6 in responders. 16 (64%) patients responded to treatment, 13 (52%) reached partial and 3 (12%) complete remission. In two recurrent cases second remission was achieved after reinstitution of the EIP regimen. Median survival time was 13 months (range 7-48 months) for responders and 5 months (range 2-11 months) for non-responders. Overall treatment was well tolerated with granulocytopenia being the most frequent toxicity. The results are encouraging for further investigations. Application of higher doses of ifosfamide with colony stimulating factors protection is planned.
近期研究指出，化疗可延长晚期无法手术的癌症患者的生命。开展了一项临床研究，以评估依托泊苷、异环磷酰胺和顺铂（EIP）联合用药治疗无法手术的非小细胞肺癌的疗效及毒性。25例患者进入该研究。治疗方案为：第1 - 3天静脉注射依托泊苷120 mg/m²，第1 - 5天静脉注射异环磷酰胺1.5 g/m²并给予美司钠保护，第1 - 5天静脉注射顺铂20 mg/m²。每4周重复一个周期，对有反应者最多重复6个周期。16例（64%）患者对治疗有反应，13例（52%）达到部分缓解，3例（12%）达到完全缓解。在2例复发患者中，重新使用EIP方案后再次获得缓解。有反应者的中位生存时间为13个月（范围7 - 48个月），无反应者为5个月（范围2 - 11个月）。总体治疗耐受性良好，粒细胞减少是最常见的毒性反应。这些结果为进一步研究提供了鼓舞。计划在有集落刺激因子保护的情况下应用更高剂量的异环磷酰胺。
